Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

Circulating tumor DNA analysis in the era of precision oncology

(2020) Rabih Said et al.   Oncotarget

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

(2019) Teofila Seremet et al.   Journal of Translational Medicine

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients

(2018) S. Valpione et al.   EUROPEAN JOURNAL OF CANCER

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

(2018) Shang-Gin Wu et al.   Molecular Cancer

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

(2018) Jenny H. Lee et al.   JAMA Oncology

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine

(2018) Ahmad Tarhini et al.   CANCER TREATMENT REVIEWS

Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples

(2018) Broderick Corless et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

(2017) Max Schreuer et al.   LANCET ONCOLOGY

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

(2016) Max Schreuer et al.   Journal of Translational Medicine

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

(2015) A. Santiago-Walker et al.   CLINICAL CANCER RESEARCH

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

(2015) Elin S. Gray et al.   Oncotarget

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastatic Volume: An Old Oncologic Concept and a New Prognostic Factor for Stage IV Melanoma Patients

(2013) V. Panasiti et al.   DERMATOLOGY

Prognostic Factors in Metastatic Melanoma Patients Treated with Biochemotherapy and Maintenance Immunotherapy

(2009) D. R. Minor et al.   ONCOLOGIST